Six-year outcomes in neovascular age-related macular degeneration with ranibizumab
Macular DiseasesRetinal Diseases
Related content
Macular DiseasesRetinal Diseases
One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration
Br J Ophthalmol.
Braimah IZ, Agarwal K, Mansour A, Chhablani J; Ziv-aflibercept Study Group
doi: 10.1136/bjophthalmol-
Macular Diseases
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: Two-Year Results
Ophthalmology.
Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group., Writing Committee:., Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd
doi: 10.1016/j.ophtha.2020.01.029.
Macular Diseases
Association of Visit Adherence and Visual Acuity in Patients With Neovascular Age-Related Macular Degeneration: Secondary Analysis of the Comparison of Age-Related Macular Degeneration Treatment Trial
JAMA Ophthalmol.
Ramakrishnan MS, Yu Y, VanderBeek BL
doi: 10.1001/jamaophthalmol.2019.4577.
Macular Diseases
Intravitreal aflibercept for neovascular age-related macular degeneration in patients aged 90 years or older: 2-year visual acuity outcomes
Eye (Lond).
Chatziralli I, Regan SO, Mohamed R, Talks J, Sivaprasad S; UK Aflibercept Users Group.
doi: 10.1038/s41433-018-0114-3.
COMMENTED
Macular Diseases
Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group
★ 3
Recommended by
Prof. Dr Daniel Barthelmes, Faculty Member
★ 3
Recommended and commented by
Dr habil. Gábor Márk Somfai, PhD, Faculty Member
doi: 10.1016/j.ophtha.2019.11.004.
COMMENTED
Macular DiseasesRetinal Diseases
Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials (CATT)
Ophthalmology.
Jaffe GJ, Ying GS, Toth CA, Daniel E, Grunwald JE, Martin DF, Maguire MG; Comparison of Age-related Macular Degeneration Treatments Trials Research Group
doi: 10.1016/j.ophtha.
Macular Diseases
Ten-Year Treatment Outcomes of Neovascular Age-Related Macular Degeneration from two regions
Am J Ophthalmol.
Gillies M, Arnold J, Bhandari S, Essex RW, Young S, Squirrell D, Nguyen V, Barthelmes D
doi: 10.1016/j.ajo.2019.10.007.
Macular Diseases
Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report Number 19
Ophthalmol Retina.
Keenan TD, Vitale S, Agrón E, Domalpally A, Antoszyk AN, Elman MJ, Clemons TE, Chew EY, Age-Related Eye Disease Study 2 Research Group.
doi: 10.1016/j.oret.2019.06.001.
Macular Diseases
Treatment Outcomes of Ranibizumab versus Aflibercept for Neovascular Age-Related Macular Degeneration: Data from the Fight Retinal Blindness! Registry
Ophthalmology.
Bhandari S, Nguyen V, Arnold J, Young S, Banerjee G, Gillies M, Barthelmes D
doi: 10.1016/j.ophtha.2019.10.006.